Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review.
about
BK channel activation by NS11021 decreases excitability and contractility of urinary bladder smooth muscleImplantable Devices for Sustained, Intravesical Drug DeliveryAdverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approachActions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes.Bladder sensory desensitization decreases urinary urgency.A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.Development of evidence-based Australian medication-related indicators of potentially preventable hospitalisations: a modified RAND appropriateness methodOxybutynin and tolterodine in a trial for treatment of overactive bladder in Iranian womenMedical management of overactive bladderEfficacy and safety of Baweidihuang-wan in women with overactive bladder: a randomized, double blind, placebo controlled trialSolifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.Muscarinic receptors in the bladder: from basic research to therapeutics.Anti-diuresis in the management of daytime urinary -incontinence.An overview of the clinical use of antimuscarinics in the treatment of overactive bladderBladder dysfunction in diabetes mellitus.Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinenceAdipose derived stem cells ameliorate hyperlipidemia associated detrusor overactivity in a rat modelPurinoceptors as therapeutic targets for lower urinary tract dysfunction.Cocaine- and amphetamine-regulated transcript peptide (CARTp): distribution and function in rat urinary bladder.Effects of a Gentle, Self-Administered Stimulation of Perineal Skin for Nocturia in Elderly Women: A Randomized, Placebo-Controlled, Double-Blind Crossover Trial.Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence: an evidence-based analysis.Role of muscarinic receptor antagonists in urgency and nocturia.Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trialsAssociation between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus.The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome.Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.Experience with imidafenacin in the management of overactive bladder disorderDevelopments in pharmacological therapy for the overactive bladder.The challenge of overactive bladder therapy: alternative to antimuscarinic agents.New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Chiropractic care of interstitial cystitis/painful bladder syndrome associated with pelvic lumbar spine dysfunction: a case seriesPharmacologic management of overactive bladder.Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.Regenerative medicine based applications to combat stress urinary incontinence.Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment.The medical treatment of overactive bladder, including current and future treatments.Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults.
P2860
Q24642564-58F1A132-3543-401E-A67A-BDB6578F1CBDQ26744682-DDDD6F85-89F8-451B-99FD-5650B6BE305EQ28742444-A68B7F10-9AA8-4C74-8800-8A2809F75874Q30483622-66B38DF0-5E73-4722-A912-BE37842EEA27Q30832054-382868DF-92C5-4BF1-B6A6-ECA7FDAF10D7Q33485538-2D0BD116-E286-4D26-979B-4C0676E538CBQ33569589-DCBDA7C6-F3D9-4E3C-AFD4-14B8FD6A3DA3Q33783024-EFA398D8-F7EB-4A45-A274-DC3BA47E2DFEQ34124065-CF709EFB-2362-4252-A98C-6E52E027CBEEQ34415046-ECF99CE4-8D8A-432B-BEDB-3517723A893CQ34543969-6468AA2F-A239-4E91-BA10-3B163260C32FQ34564708-05318416-3506-4955-A7CD-3C2F64BFC15FQ34608213-3C90DBC1-A937-4BF3-B153-F4F563411C6EQ35042575-EE5C4B80-04A4-45AD-A853-C5BE44FEF7B1Q35155238-8282C4C1-CB42-46CC-AF4A-94C0297FE145Q35166683-684F9B6F-7EFA-4A5D-8058-8F42ADF7192FQ35185998-ED6BCCAD-CD54-46F8-A229-002A587D7877Q35545723-67D36754-B56D-47F5-BA01-02A10F6F2F5EQ35679793-C412FCDC-4F13-4805-B45A-095FB3DB48D8Q35966051-B2A4037F-61E2-4DEB-9243-5D18F9104126Q36056222-D55A18B7-429C-4B0C-936D-E9D94A92040AQ36219834-8EDECFDA-0285-45C7-ADC1-411FD8BBDBA9Q36283014-224E0439-B483-4697-9B9D-CD13AE18C2A3Q36307893-1BB78339-066D-457B-9565-81F8DE58349EQ36338313-1FDBE78C-C245-4DF9-8849-53C4620FF47DQ36428471-12D58A4A-B617-4535-9315-88E4D3F7BB7BQ36428481-39D0F694-8B30-4574-A681-E29228AC55A3Q36432096-34E81201-E0ED-4D44-9330-71C23D316167Q36541100-F4536CC5-0610-4F23-9BDF-E52054DB9D05Q36566857-C60FA0A4-E7F9-4590-96A8-FD6720858FD0Q36698662-96AEC84D-8147-46A3-9062-F87FBC871F1EQ36789948-1D4F0176-8C5B-4979-B308-DE04EB6F06AFQ36997656-63DF1A05-89C3-4B46-9AA2-10D6FF633598Q37017434-C7C5F10B-8FF2-4DDE-9A63-ACE6B0B029FDQ37187453-7853B84A-2387-4479-B399-63F2CD0C5D0DQ37230811-2573738B-BC66-4CF3-8D26-B8322EE1F283Q37266543-042D551F-609B-4D27-8EAF-83BC4E8DD28DQ37589167-A1C6B7C6-268C-479A-A76A-4C45C32B7E76Q37836943-3ED43166-2F29-4563-9F30-E729CC54D714Q37946313-EF0604D0-A79A-4879-8564-188AB367BF05
P2860
Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Effectiveness of anticholinerg ...... ve bladder: systematic review.
@ast
Effectiveness of anticholinerg ...... ve bladder: systematic review.
@en
Effectiveness of anticholinerg ...... ve bladder: systematic review.
@nl
type
label
Effectiveness of anticholinerg ...... ve bladder: systematic review.
@ast
Effectiveness of anticholinerg ...... ve bladder: systematic review.
@en
Effectiveness of anticholinerg ...... ve bladder: systematic review.
@nl
prefLabel
Effectiveness of anticholinerg ...... ve bladder: systematic review.
@ast
Effectiveness of anticholinerg ...... ve bladder: systematic review.
@en
Effectiveness of anticholinerg ...... ve bladder: systematic review.
@nl
P2093
P2860
P356
P1433
P1476
Effectiveness of anticholinerg ...... ve bladder: systematic review.
@en
P2093
Gaye Ellis
Jean Hay-Smith
Kate Moore
Peter Herbison
P2860
P304
P356
10.1136/BMJ.326.7394.841
P407
P577
2003-04-01T00:00:00Z